Foscarnet Sodium

• CAT Number: A000570
• CAS Number: 63585-09-1
• Molecular Formula: CNa3O5P
• Molecular Weight: 191.95
• Purity: ≥95%
• Synonyms: 63585-09-1; Foscavir; Trisodium carboxyphosphate; Triapten; Foscarnet sodique
• Storage: -20°C
• IUPAC Name: trisodium;phosphonatoformate
• InChI: InChI=1S/CH3O5P.3Na/c2-1(3)7(4,5)6;;;/h(H,2,3)(H2,4,5,6);;;/q;3*+1/p-3
• InChIKey: DFHAXXVZCFXGOQ-UHFFFAOYSA-K
• SMILES: C(=O)([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+]

Foscarnet Sodium（Cat No.:A000570）is an antiviral agent primarily used to treat herpes viruses, including cytomegalovirus (CMV) and acyclovir-resistant herpes simplex virus (HSV) infections. Unlike other antivirals, it does not require activation by viral enzymes; instead, it directly inhibits viral DNA polymerase and reverse transcriptase, preventing viral replication. Foscarnet Sodium is administered intravenously, especially in immunocompromised patients such as those with HIV/AIDS, to manage severe or resistant infections. Its unique mechanism and broad antiviral spectrum make Foscarnet Sodium essential in managing complicated viral infections in clinical settings.

Reference

1: Yuan-Qu Y, Xiong-Pu M, Xiao-Kang J, Cai-An X. A comparison study on the
clinical effects of foscarnet sodium injection and interferon on human
immunodeficiency virus-infected patients complicated with herpes zoster. Pak J
Med Sci. 2015 Mar-Apr;31(2):309-13. doi: 10.12669/pjms.312.6536. PubMed PMID:
26101481; PubMed Central PMCID: PMC4476332.

2: Ishiyama K, Katagiri T, Hoshino T, Yoshida T, Yamaguchi M, Nakao S. Preemptive
therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk
patients after hematopoietic SCT. Bone Marrow Transplant. 2011 Jun;46(6):863-9.
doi: 10.1038/bmt.2010.201. Epub 2010 Sep 13. PubMed PMID: 20838386.

3: Yu YY, Zhang DZ, Miao XH, Zhu CL, Zhou XQ, Yu H, Si CW. [Foscarnet sodium for
treatment in patients with severe chronic hepatitis B]. Zhonghua Gan Zang Bing Za
Zhi. 2006 Nov;14(11):814-6. Chinese. PubMed PMID: 17125606.

4: Gross G, Braun D. [Efficacy and tolerability of topical foscarnet sodium in
treatment of herpes labialis. Results of post-marketing surveillance]. Hautarzt.
2006 Jan;57(1):40-6. German. PubMed PMID: 16258759.

5: FDA notifications. FDA approves generic foscarnet sodium injection. AIDS
Alert. 2005 Jul;20(7):82. PubMed PMID: 16110563.

6: Stolk LM, Hendrikse H, Chandi LS. Autoclave and long-term sterility of
foscarnet sodium admixtures. Am J Health Syst Pharm. 1995 Jan 1;52(1):103. PubMed
PMID: 12879531.

7: Iyer RP, Boal JH, Phillips LR, Thakker DR, Egan W. Synthesis, hydrolytic
behavior, and anti-HIV activity of selected acyloxyalkyl esters of trisodium
phosphonoformate (foscarnet sodium). J Pharm Sci. 1994 Sep;83(9):1269-73. PubMed
PMID: 7530302.

8: Mathew M, Das Gupta V, Bethea C. Stability of foscarnet sodium in 5% dextrose
and 0.9% sodium chloride injections. J Clin Pharm Ther. 1994 Feb;19(1):35-6.
PubMed PMID: 8188788.

9: Woods K, Steinmann W, Bruns L, Neels JT. Stability of foscarnet sodium in 0.9%
sodium chloride injection. Am J Hosp Pharm. 1994 Jan 1;51(1):88-90. PubMed PMID:
8135266.

10: DiStefano JE, Outman WR. Additional data on visual compatibility of foscarnet
sodium with morphine sulfate. Am J Hosp Pharm. 1992 Jul;49(7):1672. PubMed PMID:
1535751.